{
    "clinical_study": {
        "@rank": "45383", 
        "arm_group": {
            "arm_group_label": "Pazopanib", 
            "arm_group_type": "Experimental", 
            "description": "Pazopanib 800mg po qd until disease progression"
        }, 
        "brief_summary": {
            "textblock": "Alveolar soft part sarcoma (ASPS), a rare subset of STS (<1%) harbors t(X;17)(p11;q25)\n      translocation and produces resultant ASPL-TFE3 fusion protein. Due to its nature of high\n      expression of angiogenic factors, sunitinib and cediranib produced overall response rates of\n      55% and 43%, respectively. However, the efficacy of pazopanib is unknown in metastatic ASPS."
        }, 
        "brief_title": "Pazopanib for Metastatic Alveolar Soft Part Sarcoma", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Alveolar Soft Part Sarcoma", 
        "condition_browse": {
            "mesh_term": [
                "Sarcoma, Alveolar Soft Part", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Pazopanib, a multi-targeted anti-angiogenesis inhibitor significantly prolonged\n      progression-free survival (PFS) in patients with metastatic soft-tissue sarcoma (STS) after\n      failure to anthracycline-based regimen (pazopanib vs placebo, 4.6 vs 1.6 months, HR=0.31,\n      95% CI 0.24-0.40; P < .0001). Regarding sunitinib (continuous daily dose of 37.5mg), after a\n      median duration of 10 months, median OS and PFS were 19 months and 17 months, respectively\n      in a small retrospective study (ASPS, N=9). With regard to cediranib, 6-month PFS was over\n      60%. In addition, randomized phase II trial of sunitinib vs cediranib with cross-over at\n      disease progression was recently initiated (NCT01391962). However, the efficacy of pazopanib\n      is unknown in metastatic ASPS."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Histologically confirmed diagnosis of alveolar soft part sarcoma harboring TFE3\n             fusion at stage IV or at relapse\n\n          -  Age \u2265 18 years\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\n          -  Measurable lesion defined by RECIST v1.1\n\n          -  Chemo-na\u00efve or prior chemotherapies\n\n          -  Adequate organ function\n\n        Exclusion Criteria:\n\n          -  Prior malignancies\n\n          -  Active CNS disease\n\n          -  High-risk for gastrointestinal bleeding\n\n          -  Significant cardiovascular disease\n\n          -  Uncontrolled hypertension\n\n          -  Bleeding diathesis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113826", 
            "org_study_id": "200240"
        }, 
        "intervention": {
            "arm_group_label": "Pazopanib", 
            "description": "Pazopanib 800mg qd daily for 4 weeks = 1 cycle", 
            "intervention_name": "Pazopanib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pazopanib", 
            "Alveolar soft part sarcoma"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "contact": {
                "last_name": "Tae Min Kim, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "investigator": {
                "last_name": "Tae Min Kim, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of Pazopanib in Patients With Metastatic Alveolar Soft Part Sarcoma", 
        "overall_contact": {
            "email": "gabriel9@snu.ac.kr", 
            "last_name": "Tae Min Kim, MD, PhD", 
            "phone": "82-2-2072-3559"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ORR based on RECIST v1.1", 
            "measure": "Overall response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113826"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Tae Min Kim", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety based on CTCAE v4.0", 
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "One year"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Two years"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Seoul National University Bundang Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Asan Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Samsung Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Severance Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}